| abstract |
The invention concerns a pharmaceutical composition comprising compounds of formula (I): NZ<SUB>1</SUB>Z<SUB>2</SUB>Z<SUB>3</SUB>,<SUB/>wherein: Z<SUB>1</SUB>, Z<SUB>2</SUB>, Z<SUB>3</SUB>, independently represent: a hydrogen atom; a C<SUB>1</SUB>-C<SUB>6</SUB> alkyl group; a -SO<SUB>2</SUB>R<SUB>3</SUB> where R<SUB>3</SUB> represents a linear or branched C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, alkenyl or alkynyl group, a C<SUB>3</SUB>-C<SUB>10</SUB> cycloalkyl group or a C<SUB>6</SUB>-C<SUB>10</SUB> aryl group, a (C<SUB>1</SUB>-C<SUB>6</SUB>) alkyl (C<SUB>6</SUB>-C<SUB>14</SUB>) aryl group, a heteroaryl group in C<SUB>5</SUB>-C<SUB>10</SUB>, provided that at least one of the Z<SUB>1</SUB>, Z<SUB>2</SUB>, Z<SUB>3</SUB> represents a group of formula (II) X-R<SUB>F</SUB>-(CH<SUB>2</SUB>)<SUB>n</SUB>-SO<SUB>2</SUB>-, X, R<SUB>F</SUB> and n being such as defined in claim 1; excluding compounds for formula (I) wherein n=0 and at least one of the Z<SUB>1</SUB>, Z<SUB>2</SUB>, Z<SUB>3</SUB> groups represents CF<SUB>3</SUB>; as well as excluding the compound (C<SUB>8</SUB>F<SUB>17</SUB>) (C<SUB>2</SUB>H<SUB>5</SUB>)NH |